Six decisions of the EPO's Boards of Appeal use a string of cautionary tales to map the absolute floor of what patent applications for AI inventions must disclose — and ...
Continue reading
GPS spoofing, dual-use technology and the intellectual property question European developers must now ask
Continue reading
I am very honored to announce that I have had the opportunity to write a book in Japanese, which has been published. The b...
Continue reading
All articles
Maiwald advised Royalty Pharma on its acquisition of a portion of Neurimmune’s royalty interest in AstraZeneca’s investigational therapy cliramitug. The transaction is valued at up to USD 425 million, comprising an upfront payment of
Continue reading
Royalty Pharma and Denali have entered into a $275 million financing agreement which, pursuant to a synthetic royalty agreement, is based on future net sales of tividenofusp alfa. Tividenofusp alfa is Denali’s lead investigational TransportVehicle™-enabled enzyme rep...
Continue reading
Royalty Pharma has acquired a royalty interest in Amgen's Imdelltra, an innovative BiTE antibody for the treatment of small cell lung cancer, from BeOne Medicines for an upfront payment of $885 million. The agreement allows BeOne to sell additional royalty rights in Imdelltr...
Continue reading
Maiwald in the press
We are delighted to congratulate Iris Müller and Matthia...
Continue reading
Maiwald, one of Germany’s leading intellectual property law firms, has appointed Dr. Kerstin Wolff as Partner effective from 1 March 2026. This appointment further strengthe...
Continue reading
With retroactive effect from the beginning of the new year, Maiwald, one of Germany's leading intellectual property law firms, has appointed Martina Boidol, Dr. Anja Fux, and ...
Continue reading
All Staff News
The publication examines the Transferable Data Exclusivity Voucher (TDEV) as one of the most innovative elements of the proposed reform of European pharmaceutical legislation....
Continue reading
All publications
Maiwald has once again been recognised by FOCUS as one of Germany’s top commercial law firms in the category Patent Law.
Continue reading
We are delighted that IAM has once again recognised several Maiwald partners in the Strategy 300: The World’s Leading IP Strategists 2026 list. ...
Continue reading
We are delighted that numerous Maiwald practitioners have once again been recognised by Managing IP (MIP) in its 2026 IP STARS rankings.
Continue reading
All awards
Wed.
16
The FICPI 23rd Open Forum will take place from 16 to 18 September 2026 in Budapest, Hungary. The conference brings together IP professionals from around the world and offers an excellent opportunity to discuss current developments in intellectual property, exchange experiences and strengthen international relationships. ...
Continue reading
Mon.
21
On 21–22 September 2026, the Munich IP Forum will once again bring together leading representatives from industry, private practice, the judiciary, and the patent profession in Munich. The event provides a platform for exchanging insights on the latest developments in European patent law, with a particular focus on the Unified Patent Cou...
Continue reading
Thu.
1
On October 1 2026, we warmly invite you to the MAItalk seminar in Düsseldorf. Look forward to engaging, practice‑oriented presentations and stimulating discussions in a collegial atmosphere - ideal for exchanging ideas with experts and peers. Catering will be provided throughout the event. ...
Continue reading
Wed.
7
The AIPPI World Congress 2026 will take place in Hamburg from 7 to 10 October 2026. The annual congress is one of the key international gatherings for the IP community, bringing together members and professionals from around the world to discuss current developments and important topics in intellectual property.
Continue reading
All events